OXT and breast carcinoma: Due to changes in estrogen levels, breast cancer patients may experience decreased oxytocin activity, leading to thyroid dysfunction, decreased psychological tolerance, and symptoms such as cognitive changes, fatigue, and appetite disturbances (88).